Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XLO
HoldSinkerXilio Therapeutics, Inc. · Healthcare · United States · $59M · Avg Vol: $105K/d
38
StockRankGet insider-trade alerts
Q
45
V
40
M
46
P/E (TTM)
—
ROE
-55.0%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6.3M | 43.8M | 589.9% | 64.1M | 40.3M | 26.5M | -22.1% |
| EPS | -13.43 | -11.67 | -7.59 | -4.19 | — | — | -2.59 | -2.23 | — |
| Shares | 6.6M | 6.6M | 6.6M | 4.5M | -31.1% | — | — | — | — |
| Debt | 19.9M | 12.5M | 8.1M | 7.0M | -29.6% | 6.3M | — | — | — |
| Equity | 105.6M | 36.8M | 17.6M | 35.3M | -30.6% | — | — | — | — |
| Op CF | -75.7M | -68.6M | -18.4M | -5.0M | — | -60.6M | — | — | — |
| Inv CF | -1.9M | -0.5M | -36.0K | -0.5M | — | — | — | — | — |
| Fin CF | -69.0K | -6.5M | 29.2M | 87.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-1.7%
SMA 50SMA 200
Close
$8.93
RSI (14)
30.8
52W High
$12.74
From 52W High
0.7%
SCORE BREAKDOWN
Quality
45
ROIC
-42.9%18.5
ROE
-55.0%16.6
GP/Assets
34.5%70.4
Op. Margin
-18.7%25.2
FCF/Assets
-3.6%37.5
Piotroski
677.2
Int. Cover
—N/A
D/E Ratio
0.09x64.0
Current Ratio
4.25x67.5
Value
40
P/E (TTM)
—N/A
EV/EBITDA
2.3x25.0
P/FCF
—N/A
P/B
1.2x81.7
P/S
0.9x85.7
Div Yield
—N/A
Momentum
46
52W High %
70%51.3
RS 6M
5%71.9
SMA 50/200
1.05x66.5
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
-81%6.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$59M
P/E (Forward)
-15.5x
Gross Margin
83.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XLO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc.(you) | $59M | 38 | Hold |
| BSEM | BioStem Technologies, Inc. | $63M | 39 | Hold |
| BOLD | Boundless Bio, Inc. | $64M | 36 | Hold |
| INMB | INmune Bio Inc. | $65M | 31 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| FBIO | Fortress Biotech, Inc. | $92M | 45 | Hold |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%